baber/WOPTO huggingface dataset:
Patent NZ-548971-A (NZ)
Title: Combination of a DPP IV inhibitor and a cardiovascular compound
Inventor: HOLMES DAVID
IPC: A61P13/12
Filed: 2003-05-28
Abstract: Disclosed is a combination of (S)-1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-pyrrolidine or a pharmaceutically acceptable salt thereof and at least one therapeutic agent selected from the group consisting of losartan, olmesartan, benazepril, enalapril, lisinopril, ramipril, aliskiren, metoprolol, doxoazosin, amlodipine, fadrozole, (+)-enantiomer of fadrozole, eplerenone, candoxatril, sinorphan, omapatrilat, bosentan and hydrochlorothiazide. The combination is useful in the prevention or treatment of hypertension. (62) Divided Out of 536758
Patent NZ-552186-A (NZ)
Title: Propeller for a marine propulsion system
Inventor: ROSENKRANZ HANS-GUNTHER
IPC: F16H25/20
Filed: 2004-12-06
Abstract: A propeller with adjustable pitch propeller blades for a marine propulsion system comprising a propeller hub with a number of openings with a propeller blade 34 mounted in each opening. Each opening in the propeller hub has a hub surface 158 surrounding the opening. The base 190 of each propeller blade 34 is mounted in the opening in the propeller hub such that the base 190 of the propeller blade 34 engages the hub surface 158 surrounding the opening. Each opening in the propeller hub also contains a mechanical and non-hydraulic mechanism for disengaging the hub surface 158 surrounding the opening from the base 190 of each propeller blade 34 to allow rotation of the propeller base and therefore the propeller blade 34 about an axis transverse to the axis of rotation of the propeller by a pitch adjusting mechanism.
Patent NZ-553358-A (NZ)
Title: Sealed pack of ingredients for an individual smoothie, and associated methods and apparatuses
Inventor: DELLE COSTE RICCARDO DARIO
Filed: 2005-08-16
Abstract: Disclosed is a sealed pack that contains quantities of ingredients to make an individual smoothie portion. The ingredients comprise a flavour ingredient such as pieces of fruit (strawberries, raspberries, mango), a frozen portion of liquid such as water, fruit juice, milk, coffee or tea; and a consistency ingredient such as ice-cream, sorbet and yoghurt. The pack may be subjected to a temperature sufficiently low to maintain the frozen state of some of the ingredients in the pack. Also disclosed is a method of packaging the ingredients into the pack, or into first and second containers, or into a container with compartments for different ingredients in frozen and unfrozen states; and a method of preparing an individual smoothie using the sealed pack wherein the ingredients are blended with additional liquid; and an apparatus that uses the sealed pack for automatically vending an individual smoothie portion.
Patent NZ-553598-A (NZ)
Title: Water craft comprising a kite-type element
Inventor: WRAGE STEPHAN
IPC: B63B59/00
Filed: 2005-09-05
Abstract: A watercraft having a kite-like element, which is connected by a hawser to the watercraft, is disclosed. The kite-like element is provided with adjusting devices which are supplied with power from the watercraft. The power is transmitted from the watercraft to the kite-like element in or on the hawser. A power transmission element, which connects the watercraft and the kite-like element, is attached to the hawser, where the power transmission element is arranged in a cavity extending over the length of the hawser.
Patent NZ-570606-A (NZ)
Title: Trans-fused chromenoisoquinolines, synthesis and methods for use
Inventor: NICHOLS DAVID E
IPC: A61P25/00
Filed: 2007-02-21
Abstract: Disclosed is a chromenoisoquinoline compound of formula (I) or (II) where the substituents are as disclosed in the description and the hollow and solid wedge bond means that the hydrogen atoms are trans to each other. Also disclosed is the process for making a compound of formula (I) and the compounds that are used to make a compound of formula (I). Further disclosed is the use of a compound of formula (I) or (II) in the manufacture of a medicament for treating dopamine-related disorders and dysfunctions. Examples of compounds of formula (I) are: (-)-(6aR,12bS)-2,3-dihydroxy-6a, 7,8, 12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline hydrochloride; (+)-(6aS, 12bR)-2,3-dihydroxy-6a, 7,8, 12b-tetrahydro-6H-chromeno [3 ,4-c]isoquinoline hydrochloride; and (±)-(R*,S*)-2,3-methylenedioxy-11-methyl-6a,7-dihydro-6H-12bH-chromeno [3, 4-c ]isoquinolin-8-one.
Patent NZ-576420-A (NZ)
Title: Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses
Inventor: GOETSCH LILIANE
IPC: C07K16/00
Filed: 2007-09-27
Abstract: The present invention relates to the use of a milled homogenate and/or a suspension and/or a cell lysate, stemming from a tumor resistant to at least one anti- tumoral compound in order to immunize and generate in vitro an antibody, or one of its functional fragments, directed against a tumoral antigen specifically expressed at the surface of said resistant tumor and being possibly involved in the resistance of said resistant tumor. More particularly, the present invention is directed to such antibodies obtained by applying the method, such as the antibodies 1A6, 1A9, 2E11, 3C11 and 3G7, as well as to their use for treating cancer.
Patent NZ-579391-A (NZ)
Title: Compressible darts and methods for using these darts in subterranean walls
Inventor: SZARKA DAVID D
IPC: E21B33/13
Filed: 2004-11-10
Abstract: A dart for activating a plug located within a subterranean well bore, comprises a mandrel 10, a foam body 13 attached to the mandrel, and an elastic tether 12 attached to both the mandrel and the foam body. (62) Divided Out of 547007
Patent NZ-580752-A (NZ)
Title: Stereoisomers propofol therapeutic compounds
Inventor: JENKINS THOMAS E
IPC: C07C39/06
Filed: 2008-05-08
Abstract: Disclosed is a (-)-stereoisomer of a compound of formula (I), wherein X is H or F; or a salt thereof. Also disclosed is the use of the compound in the preparation of a medicament for inducing or maintaining general anaesthesia, promoting sedation, preventing nausea or vomiting and for treating or preventing a migraine in a subject.
Patent NZ-583150-A (NZ)
Title: Use of an antigen derived from the circumsporozoite protein (CS) protein of Plasmodium falciparum in the manufacture of a medicament for vaccinating infants against malaria
Inventor: BALLOU WILLIAM RIPLEY
IPC: A61K39/015
Filed: 2008-08-11
Abstract: Disclosed is the use of an antigen derived from the circumsporozoite protein (CS) protein of Plasmodium falciparum which is expressed at the pre-erythrocytic stage of malarial infection in combination with a pharmaceutically acceptable adjuvant, in the manufacture of a medicament for vaccinating infants against malaria wherein the target population is infants 1 week old to 50 weeks old and the CS antigen is fused to the surface antigen from hepatitis B (HBsAg).
Patent NZ-583605-A (NZ)
Title: Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
Inventor: LEE RENATA
IPC: A61K39/395
Filed: 2008-08-27
Abstract: Disclosed is an isolated antibody or fragment thereof that specifically binds to the extraceullular domain of human CXCR5wherein the antibody or fragment thereof comprises a light chain variable domain comprising: LCDR1 (RSSKSLLHSSGKTYLY); LCDR2 (RMSNLAS, RLSNLAS, RLSSNLAS, RLSSLA); LCDR3 (MQHLEYPYT); HCDR1 (GFSLIDYGVN); HCDR2 (VIWGDGTTY); and HCDR3 (IVY).
Patent NZ-587442-A (NZ)
Title: Synthetic molecule constructs
Inventor: BOVIN NICOLAI VLADIMIROVICH
IPC: A61K35/12
Filed: 2005-03-22
Abstract: Disclosed are synthetic molecule constructs which effect qualitative and quantitative changes in the expression of cell surface antigens, wherein said synthetic molecule construct includes those represented by the structure F-S1-S2-L where: F is a glycotope; S1 is 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, or 5-aminopentyl; S2 is CO(CH2)mNHCO(CH2)nCO; where n and m are independently 2 to 5; and L is a diacyl- or dialkyl- glycerophospholipid. Further disclosed is a kit which comprises a dried preparation or solution of a synthetic molecule construct as defined above. A kit which comprises a suspension in a suspending solution of cells (such as red blood cells) which incorporate said synthetic molecule construct is also disclosed.
Patent NZ-589020-A (NZ)
Title: Use of specific CTLA4 molecules for preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
Inventor: VRATSANOS GEORGE
IPC: C07K16/00
Filed: 2009-05-05
Abstract: Provided is the use of a CTLA4 molecule in the preparation of a medicament for treating undifferentiated arthritis, wherein the CTLA4 molecule binds CD80 and/or CD86 and comprises an extracellular domain of CTLA4 with a specified sequence, and beginning with alanine at position 26 or methionine at position 27 and ending with aspartic acid at position 150. Further provided is the use of CTLA4 encoding nucleic acid (ATCC No 68629) in the preparation of a medicament for treating undifferentiated arthritis.
Patent NZ-590961-A (NZ)
Title: A showerhead with relatively movable outer and inner assemblies to vary flow from wider spray to more concentrated spray with larger droplets
Inventor: CUMMINGS STEPHEN JOHN
IPC: B05B1/02
Filed: 2010-10-22
Abstract: A showerhead has relatively movable outer and inner valve assemblies to vary flow. As shown the outer sleeve assembly is retracted and this provides a wider angle spray with finer droplets. On extending the sleeve assembly a more concentrated flow is achieved with larger droplets. (62) Divided Out of 588783
Patent NZ-595658-A (NZ)
Title: Novel pyridopyrazines and their use as modulators of kinases
Inventor: CLAUS ECKHARD
IPC: C07D471/04
Filed: 2006-11-10
Abstract: ABSTRACT - 595658 The disclosure relates to pyrido[2,3-b]pyrazine derivatives of the general formulae (I), their preparation and use as medicaments for the treatment or prophylaxis of physiological and/or pathophysiological states in mammals by inhibiting two or more enzymes, wherein at least one enzyme is selected from the group consisting of Erk, Erk1 and Erk2 and at least one enzyme is selected from the group consisting of PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta and PI3K-Vps34p, in particular for the treatment of malignant and other disorders involving pathological cell proliferations.
Patent NZ-595737-A (NZ)
Title: Process for the production of safinamide and ralfinamide
Inventor: BARBANTI ELENA
IPC: A61K31/165
Filed: 2007-06-08
Abstract: 595737 Disclosed is a composition comprising safinamide or ralfinamide or a salt thereof with a pharmaceutically acceptable acid, with a content of the respective impurity (S)-2-[3-(3-fluorobenzyl)-4-(3-fluorobenzyloxy)-benzylamino]propanamide (IIa) and (S)-2-[3-(2-fluorobenzyl)-4-(2-fluorobenzyloxy)-benzylamino]propanamide (IIb) or a salt thereof with a pharmaceutically acceptable acid which is lower than 0.03% (by weight of the safinamide or ralfinamide). Further disclosed is the use of a composition comprising safinamide or ralfinamide as defined above for the manufacture of a medicament for the treatment of pain conditions including chronic and neuropathic pain, migraine, bipolar disorders, depressions, cardiovascular, inflammatory, urogenital, metabolic or gastrointestinal disorders under conditions that are not interfering with the cytochromes of the CYP450 system, in particular CYP3A4, CYP2D6, CYP2C19, CYP2C9 and do not inhibit HERG channel blocking properties.
Patent NZ-596047-A (NZ)
Title: Stabilized lipid formulation of apoptosis promoter
Inventor: HAIGHT ANTHONY R
IPC: A61K9/00
Filed: 2010-04-30
Abstract: 596047 Disclosed herein is an orally deliverable pharmaceutical composition comprising a Bcl-2 family protein inhibitory compound, e.g., ABT-263, a heavier-chalcogen antioxidant and a substantially non-aqueous lipid carrier, wherein said compound and said antioxidant are in solution in the carrier. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
Patent NZ-597023-A (NZ)
Title: Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
Inventor: TAKADA KENZO
IPC: A61P11/00
Filed: 2008-11-12
Abstract: NZ 597023 Disclosed is an isolated anti-hGM-CSF monoclonal antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof binds an epitope of hGM-CSF (SEQ ID NO: 1) comprising ELYK (SEQ ID NO: 2) and TMMASHYKQH (SEQ ID NO: 3).
Patent NZ-600144-A (NZ)
Title: Lid having a break line
Inventor: ANTIER GREGORY
IPC: B65D41/34
Filed: 2010-11-19
Abstract: The invention relates to a lid (1) comprising a tubular skirt (12) including a non-removable portion (122) permanently retained about a container neck (2) and a removable portion (121) attached in a removable manner to the neck. The non-removable and removable skirt portions are connected by a break line (20) which is breakable the first time the lid is opened. A breaking segment (28), which is delimited distinctly from the break line, is also provided to define a strand (32) therebetween. The strand has two peripheral ends (32A, 32B) and is connected to the non-removable skirt portion through a bridge (26). During first opening of the lid the break line is broken to separate the removable and non-removable portions from each other and the strand plastically deforms to provide a visual indicator of tampering. After plastic deformation the strand will subsequently fail and break at either the peripheral ends or at the bridge.
Patent NZ-600659-A (NZ)
Title: Binding apparatus for a baling maching and method of binding a bale
Inventor: AMSTEL VAN LEONARDUS HENDIRKUS MARIA
IPC: A01F15/07
Filed: 2010-11-23
Abstract: 600659 A binding apparatus for a baling machine includes means (4a,4b) for dispensing at least two strips of binding film (2a,2b) and guiding the strips of film simultaneously onto the surface of a rotating bale (6). The dispensing mechanism lays the strips of film side-by- side on the bale surface to form a combined strip (16) having a width greater than the width of each individual strip of binding film and approximately equal to the bale width. Bundling means bundle each strip of binding film to form a tail having a reduced width.
Patent NZ-604111-A (NZ)
Title: A cutting device
Inventor: PARKIN ROSS BRYAN
IPC: A01G3/00
Filed: 2010-06-01
Abstract: A cutting device (1) for use in cutting plant matter grown on a support structure and a method of use is disclosed. The support structure includes a plurality of support members (7) arranged into rows, and the cutting device includes a plurality of cutting elements (8) spaced apart from each other, characterised in that the cutting device is configured such that in use each cutting element can be inserted into a space between two support members and cut plant matter therefrom. Use of the invention for cutting kiwifruit vines and plant material is disclosed but could find use in alternate applications such as growing raspberries or other produce where growth for the next year’s production is trained away from growth which provides a current years crop. In a particularly preferred embodiment, the growing structures with which the present invention is used includes strings. The strings (4) are positioned above the growing structure so that the new canes, being new growth from the kiwifruit vine, are able to grow up and along the strings. In a particularly preferred embodiment each cutting element is a pair of reciprocating sickle bars (8). The sickle bars move in opposite directions to assist the serrated edges (8) in cutting plant matter. The movement of the cutting elements is driven by motors, which are powered by a work vehicle (6) to which the cutting device is attached.
Patent NZ-611998-A (NZ)
Title: Biodegradable compositions having pressure sensitive adhesive properties
Inventor: BECKMAN ERIC J
IPC: C09J175/04
Filed: 2011-11-15
Abstract: Disclosed is a composition comprising the reaction product of: (a) an isocyanate group-containing component having an average functionality of at least 2; selected from the group consisting of lysine diisocyanate and esters thereof, lysine triisocyanate and esters thereof, and combinations thereof: and (b) an active hydrogen group-containing component having an average functionality of at least 2, comprising (i) at least one poly-hydroxy functional compound selected from the group consisting of polyether polyols, polyester polyols, and polyhydroxyalkyl derivatives of C3-C10 hydrocarbons and (ii) at least one monohydroxy functional compound selected from the group consisting of hydroxyalkylamines and alkyl alcohols; wherein the composition is biodegradable, a solid at 22°C and below, and has pressure sensitive adhesive properties at a temperature of 37°C and relative humidity of 100%.
Patent NZ-616779-A (NZ)
Title: Modulation of apolipoprotein ciii (apociii) expression
Inventor: MULLICK ADAM
IPC: A61P3/06
Filed: 2012-04-27
Abstract: Disclosed is a use of a compound targeting ApoCIII in the manufacture of a medicament for a) treating, preventing, delaying or ameliorating pancreatitis in an animal; b) increasing HDL levels and/or improving the ratio of TG to HDL in an animal thereby preventing, delaying or ameliorating a cardiovascular disease, disorder, condition or symptom thereof or onset of a cardiovascular disease, disorder, condition or symptom thereof in an animal; c) increasing HDL levels and/or improving the ratio of TG to HDL in an animal thereby reducing the risk of a cardiovascular disease, disorder, condition or symptom in an animal; and/or d) treating, preventing, delaying or ameliorating chylomicronemia, wherein the compound is capable of inhibiting apolipoprotein C-III.
Patent NZ-623029-A (NZ)
Title: A device for improving air flow through a nasal cavity
Inventor: EDE NICHOLAS JON
IPC: A61F5/08
Filed: 2012-07-27
Abstract: Disclosed is a device for improving flow of air through a nasal cavity during physical activity. The device includes a substantially U-shaped body (6) and first (8) and second (9) adjustable bodies. The U-shaped body forms a bridge (7) for spanning adjacent nasal cavities of the wearer. The first and second adjustable bodies are mounted to opposite upright portions (7a, 7b) of the U-shaped body and each have a belt (10a, 10b) and a rib (12a, 12b). The belt is adjustable about an attachment mount (11a, 11b) on an upright portion of the U-shaped body. The rib (12a, 12b) extends outwardly and arcuately from a portion of the U-shaped body distal to the bridge. Each rib ends in a relatively large surface area which is connected to a portion of the belt. The large surface area portion of each rib is adapted for abutting internal wall surfaces of the nasal cavity of the wearer. The belt and rib form an open channel which defines an air flow pathway within the nasal cavity substantially free of obstruction. When in an operating condition, the belt or belts are tightened by a wearer to allow insertion and thereafter the belt(s) loosened to as to urge the large surface area portion of the ribs against nasal cavity walls. The large surface area portion of each rib may also include a depot or reservoir, housing a drug or medicament, which when in contact with the nasal cavity walls, is arranged to release an effective amount of an active agent.
Patent NZ-623354-A (NZ)
Title: System and method for cooling a power transmission system
Inventor: MAIOLI PAOLO
IPC: H02G5/10
Filed: 2011-10-27
Abstract: A system (CS) for cooling a power transmission system (PTS), having a cable (C1, C2, C3) which carries a current (I1, I2, I3) corresponding to transported electric power (P), is disclosed. The cooling system (CS) comprises a cooling device (CD), a power supply system (T1, T2, T3, JB), and a control unit (CU). The cooling device (CD) is arranged to remove heat from the power transmission system (PTS). The power supply system (T1, T2, T3, JB) is arranged to extract a power fraction from the cable (C1, C2, C3) and supply the extracted power to the cooling device (CD). The control unit (CU) is configured to control the amount of the extracted power with respect to a parameter of the power (P), such as current, cable temperature or power itself, transported in the cable (C1, C2, C3). When the parameter is higher than a threshold, the control unit allows a maximum power extraction. The cooling device (CD) is subsequently provided with the maximum extracted power to provide maximum cooling. When the parameter is lower than the threshold, the control unit limits the power extraction. The cooling device (CD) is subsequently provided with less extracted power, to provide less cooling. As the cooling device (CD) is not always providing maximum cooling across the whole parameter range, this system advantageously reduces cooling operating costs.
Patent NZ-630749-A (NZ)
Title: Real-time detection of periodic breathing
Inventor: RAMANAN DINESH
IPC: G16H40/63
Filed: 2014-09-11
Abstract: Disclosed is a method of detecting periodic breathing in a patient. The method includes providing a series of event interval (15070)s bounded by apnea (15060) or hypopnea (15080) events detected in the respiration of the patient. Upon closure of an event interval (15070), the event interval (15070) is processed to determine a character of the event interval (15070). The character of an event interval (15070) is either of “probably a periodic breathing cycle”, “probably not a periodic breathing cycle” and “uninformative”. A determination is made whether to change a current periodic breathing state indicating whether a periodic breathing episode is in progress, based on a history of event interval (15070) characterisations that is long compared to the typical length of a periodic breathing cycle.
Patent NZ-703628-A (NZ)
Title: Diazepinone derivatives useful for the treatment of fragile x syndrome, parkinsons or reflux disease
Inventor: CARCACHE DAVID
IPC: C07D471/04
Filed: 2013-08-21
Abstract: The invention relates to compound of the formula (I) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it. The diazepinone derivatives of formula (I) are mGluR5 antagonists useful in a range of disorders such as Fragile X syndrome, Parkinson’s disease and Reflux disease.
Patent NZ-704157-A (NZ)
Title: Engineering t-cell receptors
Inventor: SMITH SHEENA N
IPC: C12N15/12
Filed: 2013-07-26
Abstract: The disclosure relates to methods of producing modified TCRs and single chain TCRs that can bind to a non-cognate peptide-MHC not bound by the wild-type receptor. TCRs with de novo binding to a specific peptide-major histocompatibility complex (MHC) product can be isolated by: 1) mutagenizing a T cell receptor protein coding sequence to generate a variegated population of mutants (a library), 2) selection of the library of TCR mutants with the specific peptide-MHC, wherein the mutant T cell receptor binds to HLA.A2 and a non-cognate peptide, and wherein the HLA.A2:non-cognate peptide is SURV:HLA.A2, using a process of directed evolution and a “display” methodology (e.g., yeast, phage, mammalian cell) and the peptide-MHC ligand. The process can be repeated to identify TCR variants with improved affinity for the selecting peptide-MHC ligand.